References
- Precision medicine [Internet]. Natl Cancer Inst. 2015. [cited 2018 Dec 7]. Available from: https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
- Sun J, Wei Q, Zhou Y, et al. A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol [Internet]. 2017;11. [cited 2018 Dec 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629554/
- Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the “high-hanging fruit”. Nat Rev Drug Discov. 2018;17:197–223.
- Marsden CJ, Eckersley S, Hebditch M, et al. The use of antibodies in small-molecule drug discovery. J Biomol Screen. 2014;19:829–838.
- Tyler DS, Vappiani J, Cañeque T, et al. Click chemistry enables preclinical evaluation of targeted epigenetic therapies. Science. 2017;356:1397–1401.
- Luchini A, Espina V, Liotta LA. Protein painting reveals solvent-excluded drug targets hidden within native protein–protein interfaces. Nat Commun. 2014;5:4413.
- Dailing A, Luchini A, Liotta L. Unlocking the secrets to protein-protein interface drug targets using structural mass spectrometry techniques. Expert Rev Proteomics. 2015;12:457–467.
- Lee J, Han JJ, Altwerger G, et al. Proteomics and biomarkers in clinical trials for drug development. J Proteomics. 2011;74:2632–2641.
- Kuenzi BM, Remsing Rix LL, Stewart PA, et al. Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nat Chem Biol. 2017;13:1222–1231.
- Emdal KB, Pedersen A-K, Bekker-Jensen DB, et al. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. Sci Signal. 2018;11:eaap9752.
- Bhatt V. Current market and regulatory landscape of biosimilars. Am J Manag Care. 2018;24:S0.
- Rugo HS, Rifkin RM, Declerck P, et al. Demystifying biosimilars: development, regulation and clinical use. Future Oncol [Internet]. 2018. Available from: https://www.futuremedicine.com/doi/10.2217/fon-2018-0680
- Isaacs J, Gonçalves J, Strohal R, et al. The biosimilar approval process: how different is it? Consid Med. 2017;1:3–6.
- Iwamoto N, Shimada T. Recent advances in mass spectrometry-based approaches for proteomics and biologics: great contribution for developing therapeutic antibodies. Pharmacol Ther. 2018;185:147–154.
- Russo P, Hood BL, Bateman NW, et al. quantitative mass spectrometry by isotope dilution and Multiple Reaction Monitoring (MRM). Methods Mol Biol Clifton NJ. 2017;1606:313–332.
- Bourmaud A, Gallien S, Domon B. Parallel reaction monitoring using quadrupole-Orbitrap mass spectrometer: principle and applications. Proteomics. 2016;16:2146–2159.
- Peterson AC, Russell JD, Bailey DJ, et al. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics MCP. 2012;11:1475–1488.
- Shi T, Song E, Nie S, et al. Advances in targeted proteomics and applications to biomedical research. Proteomics. 2016;16:2160–2182.
- El Kennani S, Adrait A, Permiakova O, et al. Systematic quantitative analysis of H2A and H2B variants by targeted proteomics. Epigenetics Chromatin. 2018;11:2.
- Chen Y, Britton D, Wood ER, et al. Quantitative proteomics of breast tumors: tissue quality assessment to clinical biomarkers. Proteomics. 2017;17:1600335.
- Valdés A, Lewitt M, Wiss E, et al. Development of a parallel reaction monitoring-MS method to quantify IGF proteins in dogs and a case of nonislet cell tumor hypoglycemia. J Proteome Res. 2019;18:18–29.
- Schlüter H, Apweiler R, Holzhütter H-G, et al. Finding one’s way in proteomics: a protein species nomenclature. Chem Cent J. 2009;3:11.
- Aebersold R, Agar JN, Amster IJ, et al. How many human proteoforms are there? Nat Chem Biol. 2018;14:206–214.
- Mueller C, deCarvalho AC, Mikkelsen T, et al. Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic–genomic correlations. Cancer Res. 2014;74:818–828.
- Wolf DM, Yau C, Sanil A, et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017;3:31.
- Possemato AP, Paulo JA, Mulhern D, et al. Multiplexed phosphoproteomic profiling using titanium dioxide and immunoaffinity enrichments reveals complementary phosphorylation events. J Proteome Res. 2017;16:1506–1514.
- Arshad OA, Danna V, Petyuk VA, et al. An integrative analysis of tumor proteomic and phosphoproteomic profiles to examine the relationships between kinase activity and phosphorylation. Mol Cell Proteomics MCP. 2019. doi: 10.1074/mcp.RA119.001540.
- Narumi R, Murakami T, Kuga T, et al. A strategy for large-scale phosphoproteomics and SRM-based validation of human breast cancer tissue samples. J Proteome Res. 2012;11:5311–5322.
- Wang D, Tan G, Wang H, et al. Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry. J Pharm Biomed Anal. 2019;166:357–363.
- Geijsen AJMR, Brezina S, Keski-Rahkonen P, et al. Plasma metabolites associated with colorectal cancer: A discovery-replication strategy. Int J Cancer. 2019;145:1221–1231.
- Li H, Mao Y, Xiong Y, et al. A comprehensive proteome analysis of Peripheral Blood Mononuclear Cells (PBMCs) to identify candidate biomarkers of pancreatic cancer. Cancer Genomics Proteomics. 2019;16:81–89.
- Sun F, Suttapitugsakul S, Wu R. Enzymatic tagging of glycoproteins on the cell surface for their global and site-specific analysis with mass spectrometry. Anal Chem. 2019;91:4195–4203.
- Fredolini C, Meani F, Reeder KA, et al. Concentration and preservation of very low abundance biomarkers in urine, such as Human Growth Hormone (hGH), by cibacron blue F3G-A loaded hydrogel particles. Nano Res. 2008;1:502–518.
- Magni R, Espina BH, Liotta LA, et al. Hydrogel nanoparticle harvesting of plasma or urine for detecting low abundance proteins. J Vis Exp JoVE. 2014;90:e51789.
- Castagna A, Cecconi D, Sennels L, et al. Exploring the hidden human urinary proteome via ligand library beads. J Proteome Res. 2005;4:1917–1930.
- Tubaon RM, Haddad PR, Quirino JP. Sample clean-up strategies for ESI mass spectrometry applications in bottom-up proteomics: trends from 2012 to 2016. Proteomics. 2017;17:1700011.
- León IR, Schwämmle V, Jensen ON, et al. Quantitative assessment of in-solution digestion efficiency identifies optimal protocols for unbiased protein analysis. Mol Cell Proteomics MCP. 2013;12:2992–3005.
- Huang BX, Kim H-Y. Effective identification of Akt interacting proteins by two-step chemical crosslinking, co-immunoprecipitation and mass spectrometry. PloS One. 2013;8:e61430.
- Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20:1981–1989.
- Akbani R, Ng PKS, Werner HMJ, et al. A pan-cancer proteomic perspective on the cancer genome atlas. Nat Commun. 2014;5:3887.
- Akbani R, Becker K-F, Carragher N, et al. Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society. Mol Cell Proteomics MCP. 2014;13:1625–1643.
- Mueller C, Liotta LA, Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol. 2010;4:461–481.
- Hayashi N, Manyam GC, Gonzalez-Angulo AM, et al. Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. Oncologist. 2014;19:909–914.
- Johnston HJ, Boys SK, Makda A, et al. Naturally inspired peptide leads: alanine scanning reveals an actin-targeting thiazole analogue of bisebromoamide. ChemBioChem. 2016;17:1621–1627.
- Pawlak M, Carragher NO. Reverse phase protein arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models. Drug Discov Today Technol. 2017;23:7–16.
- Partolina M, Thoms HC, MacLeod KG, et al. Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array. Cell Death Discov. 2017;3:16077.
- Gallagher RI, Espina V. Reverse phase protein arrays: mapping the path towards personalized medicine. Mol Diagn Ther. 2014;18:619–630.
- Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell. 2003;3:317–325.
- O’Farrell AC, Miller IS, Evans R, et al. Implementing reverse phase protein array profiling as a sensitive method for the early pre-clinical detection of off-target toxicities associated with sunitinib malate. Proteomics Clin Appl. 2019;13:e1800159.
- Davis JB, Calvert V, Roberts S, et al. Induction of nerve growth factor by phorbol 12-myristate 13-acetate is dependent upon the mitogen activated protein kinase pathway. Heliyon. 2018;4:e00617.
- He S, Fu Y, Guo J, et al. Cofilin hyperactivation in HIV infection and targeting the cofilin pathway using an anti-α4β7 integrin antibody. Sci Adv. 2019;5:eaat7911.
- Saxena C. Affinity-based chemoproteomics with small molecule-peptide conjugates. Methods Mol Biol Clifton NJ. 2012;803:39–54.
- Drewes G, Knapp S. Chemoproteomics and chemical probes for target discovery. Trends Biotechnol. 2018;36:1275–1286.
- Chen Y-C, Zhang C. A chemoproteomic method for identifying cellular targets of covalent kinase inhibitors. Genes Cancer. 2016;7:148–153.
- Counihan JL, Wiggenhorn AL, Anderson KE, et al. Chemoproteomics-enabled covalent ligand screening reveals ALDH3A1 as a lung cancer therapy target. ACS Chem Biol. 2018;13:1970–1977.
- Zhou J, Mock ED, Martella A, et al. Activity-based protein profiling identifies α-ketoamides as inhibitors for phospholipase A2 group XVI. ACS Chem Biol. 2019;14:164–169.
- Scheer S, Ackloo S, Medina TS, et al. A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. Nat Commun. 2019;10:19.
- Li W, Zhou Y, Tang G, et al. Chemoproteomics reveals the antiproliferative potential of Parkinson’s disease kinase inhibitor LRRK2-IN-1 by targeting PCNA protein. Mol Pharm. 2018;15:3252–3259.
- Dalvit C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov Today. 2009;14:1051–1057.
- Luise N, Wyatt PG. Diversity-oriented synthesis of bicyclic fragments containing privileged azines. Bioorg Med Chem Lett. 2019;29:248–251.
- Dick BL, Cohen SM. Metal-binding isosteres as new scaffolds for metalloenzyme inhibitors. Inorg Chem. 2018;57:9538–9543.
- Qiu H, Liu-Bujalski L, Caldwell RD, et al. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit. Bioorg Med Chem Lett. 2018;28:2939–2944.
- White GV, Edgar EV, Holmes DS, et al. Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for netherton syndrome. Bioorg Med Chem Lett. 2019;29:821–825.
- Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer [Internet]. 2018;17. [cited 2018 Dec 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817855/
- Rosell M, Fernández-Recio J. Hot-spot analysis for drug discovery targeting protein-protein interactions. Expert Opin Drug Discov. 2018;13:327–338.
- Jiang J, Wang N, Chen P, et al. Prediction of protein hotspots from whole protein sequences by a random projection ensemble system. Int J Mol Sci. 2017;18. [cited 2018 Dec 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536031/
- Ofran Y, Rost B. Protein–protein interaction hotspots carved into sequences. PLoS Comput Biol [internet]. 2007;3. [cited 2018 Dec 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1914369/
- Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011;18:1414–1424.
- Ku B, Liang C, Jung JU, et al. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 2011;21:627–641.
- Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–681.
- Garland W, Benezra R, Chaudhary J. Chapter fifteen - targeting protein–protein interactions to treat cancer—recent progress and future directions. In: Desai MC, editor. Annual reports in medicinal chemistry [Internet]. Academic Press; 2013. p. 227–245. [cited 2018 Dec 10]. Available from: http://www.sciencedirect.com/science/article/pii/B9780124171503000156
- Mullard A. Pioneering apoptosis-targeted cancer drug poised for FDA approval. Nat Rev Drug Discov. 2016;15:147–149.
- Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
- Press Announcements. FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality [Internet]. 2018 [cited 2018 Dec 10]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm495253.htm
- Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology [Internet]. 2017;7. [cited 2018 Dec 10]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739549/
- Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes. Oncol Targets Ther. 2016;9:5023–5039.
- Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6:e1792.
- NCI Dictionary of Cancer Terms. Immune checkpoint inhibitor. [Internet]. Natl Cancer Inst. 2011. [cited 2018 Dec 10]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor
- Zak KM, Kitel R, Przetocka S, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure. 2015;23:2341–2348.
- Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer [Internet]. 2018;6. [cited 2018 Dec 10]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778665/
- Lee JY, Lee HT, Shin W, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 2016;7. [cited 2018 Dec 10]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095608/
- Lee HT, Lee JY, Lim H, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017;7. [cited 2018 Dec 10]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514103/
- Research C for DE and. FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. FDA [Internet]. 2019; [cited 2019 May 19]; Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma
- “I want what Jimmy Carter had”: patients clamor for Keytruda [Internet]. STAT. 2015 [cited 2018 Sep 20]. Available from: https://www.statnews.com/2015/12/18/jimmy-carter-cancer-drug-keytruda/
- Wang T, Wu X, Guo C, et al. Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway. J Med Chem [Internet]. 2018 Dec 10. DOI:10.1021/acs.jmedchem.8b00990
- Verdone L, Caserta M, Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem Cell Biol Biochim Biol Cell. 2005;83:344–353.
- Xu Y, Vakoc CR. Targeting cancer cells with BET bromodomain inhibitors. Cold Spring Harb. Perspect Med [Internet]. 2017;7. [cited 2018 Dec 11]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495050/
- Wang Q, Li Y, Xu J, et al. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations. Sci Rep. 2017;7:8857.
- Andrieu G, Belkina AC, Denis GV. Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today Technol. 2016;19:45–50.
- Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers (Basel). 2011;3:994–1013.
- Liao G, Yang D, Ma L, et al. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy. Eur J Med Chem. 2018;159:1–9.
- Zhao Y, Aguilar A, Bernard D, et al. Small-molecule inhibitors of the MDM2–p53 protein–protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem. 2015;58:1038–1052.
- Tisato V, Voltan R, Gonelli A, et al. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. J Hematol OncolJ Hematol Oncol. 2017;10:133.
- Bai L, Smith DC, Wang S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther. 2014;144:82–95.
- Beug ST, Beauregard CE, Healy C, et al. Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nat Commun. 2017;8. [cited 2018 Dec 11]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330852/
- Fulda S. Promises and challenges of smac mimetics as cancer therapeutics. Clin Cancer Res. 2015;21:5030–5036.
- Bakail M, Ochsenbein F. Targeting protein–protein interactions, a wide open field for drug design. Comptes Rendus Chim. 2016;19:19–27.
- Shi D, Nannenga BL, Iadanza MG, et al. Three-dimensional electron crystallography of protein microcrystals. eLife [internet]. 2013;2. [cited 2018 Dec 11]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831942/
- Henninot A, Collins JC, Nuss JM. The current state of peptide drug discovery: back to the future? J Med Chem. 2018;61:1382–1414.
- Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38:406–424.
- Morrison C. Constrained peptides’ time to shine? Nat Rev Drug Discov. 2018;17:531–533.
- Cary DR, Ohuchi M, Reid PC, et al. Constrained peptides in drug discovery and development. J Synth Org Chem Jpn. 2017;75:1171–1178.
- Meric-Bernstam F, Saleh MN, Infante JR, et al. Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J Clin Oncol. 2017;35:2505.
- Otvos L, Wade JD. Current challenges in peptide-based drug discovery. Front Chem [Internet]. 2014;2. [cited 2018 Dec 12]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126357/
- Nielsen DS, Shepherd NE, Xu W, et al. Orally absorbed cyclic peptides. Chem Rev. 2017;117:8094–8128.
- Eckhardt B, Grosse W, Essen L-O, et al. Structural characterization of a β-turn mimic within a protein–protein interface. Proc Natl Acad Sci. 2010;107:18336–18341.
- Möller GP, Müller S, Wolfstädter BT, et al. Oxetanyl amino acids for peptidomimetics. Org Lett. 2017;19:2510–2513.
- Hamley IW. PEG–peptide conjugates. Biomacromolecules. 2014;15:1543–1559.
- Muheem A, Shakeel F, Jahangir MA, et al. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm J. 2016;24:413–428.
- Sharma A, Reddy P, Kuppermann BD, et al. Biosimilars in ophthalmology: “Is there a big change on the horizon?”. Clin Ophthalmol Auckl NZ. 2018;12:2137–2143.
- U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry [Internet]. 2015. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
- Lee KH, Lee J, Bae JS, et al. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product. mAbs. 2018;10:380–396.
- Thennati R, Singh SK, Nage N, et al. Analytical characterization of recombinant hCG and comparative studies with reference product. Biol Targets Ther. 2018;12:23–35.
- Hajba L, Szekrényes Á, Borza B, et al. On the glycosylation aspects of biosimilarity. Drug Discov Today. 2018;23:616–625.
- Giansanti P, Tsiatsiani L, Low TY, et al. Six alternative proteases for mass spectrometry–based proteomics beyond trypsin. Nat Protoc. 2016;11:993–1006.
- Tsiatsiani L, Heck AJR. Proteomics beyond trypsin. Febs J. 2015;282:2612–2626.
- Paik Y-K, Lane L, Kawamura T, et al. Launching the C-HPP neXt-CP50 pilot project for functional characterization of identified proteins with no known function. J Proteome Res. 2018;17:4042–4050.
- Schafferhans A, O’Donoghue SI, Heinzinger M, et al. Dark proteins important for cellular function. PROTEOMICS. 2018;18:1800227.
- Perdigão N, Heinrich J, Stolte C, et al. Unexpected features of the dark proteome. Proc Natl Acad Sci USA. 2015;112:15898–15903.
- Bhowmick A, Brookes DH, Yost SR, et al. Finding our way in the dark proteome. J Am Chem Soc. 2016;138:9730–9742.
- Perdigão N, Rosa A. Dark proteome database: studies on dark proteins. High Throughput. 2019;8:8.
- Issa NT, Wathieu H, Ojo A, et al. Drug metabolism in preclinical drug development: a survey of the discovery process, toxicology, and computational tools. Curr Drug Metab. 2017;18:556–565.
- Agrawal S, Khazaeni B. Acetaminophen toxicity. statpearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 [cited 2019 May 18]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK441917/